Advertisement

Heart Failure Reviews

, Volume 9, Issue 3, pp 179–185 | Cite as

Overview of Acutely Decompensated Congestive Heart Failure (ADHF): A Report from the ADHERE Registry

  • Gregg C. Fonarow
  • ADHERE® Scientific Advisory Committee
  • Eliot Corday
Article

Abstract

Acute decompensated heart failure (ADHF) has emerged as a major public health problem, and HF has become the leading cause of hospitalization in persons over 65 years of age. It is estimated that there are 6.5 million hospital days attributed to ADHF each year. Patients hospitalized with ADHF face a substantial risk of readmission, as high as 50% by 6 months after discharge. Despite the large number of patients hospitalized and this substantial risk, data on these patients have been limited and there has been little effort to improve the quality of care for patients hospitalized with ADHF. The Acute Decompensated Heart Failure National Registry (ADHERE®) was designed to bridge this gap in knowledge and care by prospectively studying the characteristics, management, and outcomes of a broad spectrum of patients hospitalized with ADHF. Participating community and university hospitals identified patients with a primary or secondary discharge diagnosis of HF and collected medical history, management, treatments, and health outcomes via secure Web browser technology. As of October 2004, more than 160,000 patients from 281 hospitals have been enrolled. These patients differ substantially from those typically enrolled in randomized clinical trials. Initial data from the ADHERE registry have provided important insights into the clinical characteristics, patterns of care, and outcomes of patients with ADHF. ADHERE has documented significant delays in diagnosis and initiation of ADHF therapies as well as a substantial under-use of evidenced-based, guideline-recommended chronic HF therapies at hospital discharge. As such, there are substantial opportunities to improve the quality of care for ADHF patients in the nation’s hospitals.

Keywords

acute decompensated heart failure hospitalization registry mortality quality of care 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101–2113.Google Scholar
  2. 2.
    American Heart Association, American Stroke Association. Heart Disease and Stroke Statistics—2004 Update. American Heart Association. Available at: http://www.americanheart.org/downloadable/heart/1072969766940HSStats2004Update.pdf. Accessed September 13, 2004.
  3. 3.
    Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997;157:99–104.Google Scholar
  4. 4.
    Franciosa JA, Abraham WT, Fowler M, et al. Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians. J Card Fail 2000;6:264–271.Google Scholar
  5. 5.
    Adams KF, O’Connor CM, Oren RM, et al. Development of a multicenter heart failure database: Initial report from the United investigators to Evaluate Heart Failure. J Card Fail 2000;6:2–56.Google Scholar
  6. 6.
    Fonarow GC, Adams K, Strausser BP, for the ADHERE Scientific Advisory Committee and Investigators. ADHERE (Acute Decompensated Heart Failure National Registry): Rationale, design, and subject population [abstract 175]. J Card Fail 2002;8(4 suppl):S49.Google Scholar
  7. 7.
    ADHERE™ Acute Decompensated Heart Failure National Registry. 3rd Quarter 2003 National Benchmark Report. Available at: http://www.adhereregistry.com/national_BMR/index.html Accessed June 9, 2004.
  8. 8.
    Emerman CL, Peacock WF, Fonarow GC. Effect of emergency department initiation of vasoactive infusion therapy on heart failure length of stay [abstract 162]. Ann Emerg Med 2002;40(suppl 4):S46.Google Scholar
  9. 9.
    Cuffe MS, Califf RM, Adams KFJ, et al., for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541–1547.Google Scholar
  10. 10.
    Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel T, The ADHERE Scientific Advisory Committee and Investigators. Comparison of in-hospital mortality in patients treated with nesiritide vs. other parenteral vasoactive medications for acutely decompensated heart failure: an analysis from a large prospective registry database [abstract 298]. J Card Fail 2003;9(suppl 1):S81.Google Scholar
  11. 11.
    Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819–822.Google Scholar
  12. 12.
    Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med2002;3(suppl 3):S2–S10.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Gregg C. Fonarow
    • 1
    • 2
  • ADHERE® Scientific Advisory Committee
  • Eliot Corday
    • 1
  1. 1.Ahmanson-UCLA Cardiomyopathy CenterUniversity of California Los AngelesLos AngelesUSA
  2. 2.UCLA Division of CardiologyAhmanson-UCLA Cardiomyopathy CenterLos AngelesUSA

Personalised recommendations